Viewing Study NCT07421856


Ignite Creation Date: 2026-03-26 @ 3:17 PM
Ignite Modification Date: 2026-04-06 @ 2:14 AM
Study NCT ID: NCT07421856
Status: NOT_YET_RECRUITING
Last Update Posted: 2026-02-19
First Post: 2025-12-17
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.
Sponsor: Hebei Senlang Biotechnology Inc., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module